Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Colorectal Neoplasms

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    August 2018
  1. MADI A, Fisher D, Maughan TS, Colley JP, et al
    Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Eur J Cancer. 2018;102:31-39.
    PubMed     Text format     Abstract available


    July 2018
  2. ARANDA E, Garcia Alfonso P, Benavides M, Sanchez Ruiz A, et al
    First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    Eur J Cancer. 2018 Jul 24. pii: S0959-8049(18)30938.
    PubMed     Text format     Abstract available


  3. HEGEWISCH-BECKER S, Nopel-Dunnebacke S, Hinke A, Graeven U, et al
    Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Eur J Cancer. 2018;101:105-113.
    PubMed     Text format     Abstract available


  4. GELLI M, Huguenin JFL, de Baere T, Benhaim L, et al
    Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
    Eur J Cancer. 2018;100:94-103.
    PubMed     Text format     Abstract available


    June 2018
  5. GOEY KKH, Sorbye H, Glimelius B, Adams RA, et al
    Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
    Eur J Cancer. 2018;100:35-45.
    PubMed     Text format     Abstract available


  6. STOCKER G, Hacker UT, Fiteni F, John Mahachie J, et al
    Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
    Eur J Cancer. 2018;99:49-57.
    PubMed     Text format     Abstract available


    May 2018
  7. APARICIO T, Ducreux M, Faroux R, Barbier E, et al
    Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
    Eur J Cancer. 2018;98:1-9.
    PubMed     Text format     Abstract available


  8. APARICIO T, Bouche O, Francois E, Retornaz F, et al
    Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    Eur J Cancer. 2018;97:16-24.
    PubMed     Text format     Abstract available


  9. AUCLIN E, Andre T, Taieb J, Benetkiewicz M, et al
    Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.
    Eur J Cancer. 2018 May 3. pii: S0959-8049(18)30782.
    PubMed     Text format    


  10. GOEY KKH, Mahmoud R, Sorbye H, Glimelius B, et al
    Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
    Eur J Cancer. 2018;96:115-124.
    PubMed     Text format     Abstract available


    April 2018
  11. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Eur J Cancer. 2018;96:105-110.
    PubMed     Text format     Abstract available


  12. MATSUDA C, Ishiguro M, Teramukai S, Kajiwara Y, et al
    A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Eur J Cancer. 2018;96:54-63.
    PubMed     Text format     Abstract available


    March 2018
  13. TACHON G, Frouin E, Karayan-Tapon L, Auriault ML, et al
    Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
    Eur J Cancer. 2018 Mar 5. pii: S0959-8049(18)30121.
    PubMed     Text format    


  14. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.
    Eur J Cancer. 2018;94:1-5.
    PubMed     Text format     Abstract available


    February 2018
  15. YOSHINO T, Hsu Y, Nasroulah F
    Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
    Eur J Cancer. 2018 Feb 9. pii: S0959-8049(18)30084.
    PubMed     Text format    


  16. ZOU D, Lou J, Ke J, Mei S, et al
    Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression.
    Eur J Cancer. 2018;93:1-9.
    PubMed     Text format     Abstract available


    January 2018
  17. VAN ROOIJEN KL, Shi Q, Goey KKH, Meyers J, et al
    Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    Eur J Cancer. 2018;91:99-106.
    PubMed     Text format     Abstract available


  18. IBRAHIM S, Raoul W, Lecomte T, Paintaud G, et al
    Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31461.
    PubMed     Text format    


    December 2017
  19. VAN CUTSEM E, Mayer RJ, Laurent S, Winkler R, et al
    The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Eur J Cancer. 2017;90:63-72.
    PubMed     Text format     Abstract available


    November 2017
  20. MODEST DP, Denecke T, Pratschke J, Ricard I, et al
    Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Eur J Cancer. 2017;88:77-86.
    PubMed     Text format     Abstract available


  21. COHEN R, Buhard O, Cervera P, Hain E, et al
    Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Eur J Cancer. 2017;86:266-274.
    PubMed     Text format     Abstract available


    October 2017
  22. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Eur J Cancer. 2017;86:197-206.
    PubMed     Text format     Abstract available


  23. KEIKES L, Koopman M, Tanis PJ, Lemmens VEPP, et al
    Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.
    Eur J Cancer. 2017;86:166-177.
    PubMed     Text format     Abstract available


  24. PREVOSTEL C, Blache P
    The dose-dependent effect of SOX9 and its incidence in colorectal cancer.
    Eur J Cancer. 2017;86:150-157.
    PubMed     Text format     Abstract available


  25. MALKA D, Rotolo F, Boige V
    First-line treatment in metastatic colorectal cancer: Important or crucial?
    Eur J Cancer. 2017;84:363-366.
    PubMed     Text format    


    September 2017
  26. TURATI F, Bravi F, Di Maso M, Bosetti C, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk.
    Eur J Cancer. 2017;85:86-94.
    PubMed     Text format     Abstract available


    August 2017
  27. MODEST DP, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
    Eur J Cancer. 2017;84:262-269.
    PubMed     Text format     Abstract available


  28. MAY-WILSON S, Sud A, Law PJ, Palin K, et al
    Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
    Eur J Cancer. 2017;84:228-238.
    PubMed     Text format     Abstract available


  29. STINTZING S, Tejpar S, Gibbs P, Thiebach L, et al
    Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.
    Eur J Cancer. 2017;84:69-80.
    PubMed     Text format     Abstract available


  30. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed     Text format    


    July 2017
  31. TOPI G, Ehrnstrom R, Jirstrom K, Palmquist I, et al
    Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer.
    Eur J Cancer. 2017;83:279-289.
    PubMed     Text format     Abstract available


  32. CASCINU S, Rosati G, Nasti G, Lonardi S, et al
    Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase
    Eur J Cancer. 2017;83:106-115.
    PubMed     Text format     Abstract available


  33. KATONA BW, Yang YX
    Colorectal cancer risk associated with the CHEK2 1100delC variant.
    Eur J Cancer. 2017;83:103-105.
    PubMed     Text format    


  34. STINTZING S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, et al
    Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Eur J Cancer. 2017;79:50-60.
    PubMed     Text format     Abstract available


    June 2017
  35. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;82:92-102.
    PubMed     Text format     Abstract available


  36. EMILE JF, Julie C, Le Malicot K, Lepage C, et al
    Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Eur J Cancer. 2017;82:16-24.
    PubMed     Text format     Abstract available


  37. CARRATO A, Abad A, Massuti B, Gravalos C, et al
    First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Eur J Cancer. 2017;81:191-202.
    PubMed     Text format     Abstract available


  38. YAMANO T, Yamauchi S, Kimura K, Babaya A, et al
    Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.
    Eur J Cancer. 2017;81:90-101.
    PubMed     Text format     Abstract available


  39. THOMSEN M, Guren MG, Skovlund E, Glimelius B, et al
    Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
    Eur J Cancer. 2017;81:26-35.
    PubMed     Text format     Abstract available


  40. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    PubMed     Text format     Abstract available


  41. YOSHINO T, Obermannova R, Bodoky G, Garcia-Carbonero R, et al
    Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Eur J Cancer. 2017;78:61-69.
    PubMed     Text format     Abstract available


  42. ADAM R, Yi B, Innominato PF, Barroso E, et al
    Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
    Eur J Cancer. 2017;78:7-15.
    PubMed     Text format     Abstract available


    April 2017
  43. ROVERS KP, Simkens GA, Vissers PA, Lemmens VE, et al
    Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.
    Eur J Cancer. 2017;75:132-140.
    PubMed     Text format     Abstract available


    March 2017
  44. FROUWS MA, Rademaker E, Bastiaannet E, van Herk-Sukel MP, et al
    The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
    Eur J Cancer. 2017;77:24-30.
    PubMed     Text format     Abstract available


  45. BERGER MD, Yamauchi S, Cao S, Hanna DL, et al
    Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Eur J Cancer. 2017;77:13-20.
    PubMed     Text format     Abstract available


  46. HOLCH JW, Heinemann V
    Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients.
    Eur J Cancer. 2017;77:1-2.
    PubMed     Text format    


  47. KWAKMAN JJ, Simkens LH, Mol L, Kok WE, et al
    Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Eur J Cancer. 2017;76:93-99.
    PubMed     Text format     Abstract available


  48. DEL RIO M, Mollevi C, Bibeau F, Vie N, et al
    Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    Eur J Cancer. 2017;76:68-75.
    PubMed     Text format     Abstract available


  49. TREASURE T, Williams NR
    Best available evidence related to clinical benefit of surgical resection in multimodality treatment of metastatic colorectal cancer indicates that a randomised controlled trial is warranted.
    Eur J Cancer. 2017;75:310-312.
    PubMed     Text format    


    February 2017
  50. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    PubMed     Text format     Abstract available


  51. FRANKEN MD, van Rooijen EM, May AM, Koffijberg H, et al
    Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Eur J Cancer. 2017;75:204-212.
    PubMed     Text format     Abstract available


  52. HUGEN N, Nagtegaal ID
    Distinct metastatic patterns in colorectal cancer patients based on primary tumour location.
    Eur J Cancer. 2017;75:3-4.
    PubMed     Text format    


  53. PAPAMICHAEL D, Aapro M
    Geriatric factors and outcomes in metastatic colorectal cancer.
    Eur J Cancer. 2017 Feb 10. pii: S0959-8049(16)32566.
    PubMed     Text format    


  54. MECHERA R, Schuster T, Rosenberg R, Speich B, et al
    Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;72:84-94.
    PubMed     Text format     Abstract available


  55. SCHAFFAR R, Rachet B, Belot A, Woods LM, et al
    Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.
    Eur J Cancer. 2017;72:78-83.
    PubMed     Text format     Abstract available


  56. FRIN AC, Evesque L, Gal J, Benezery K, et al
    Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.
    Eur J Cancer. 2017;72:124-136.
    PubMed     Text format     Abstract available


    January 2017
  57. MODEST DP, Neumann UP, Pratschke J
    FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Eur J Cancer. 2017 Jan 9. pii: S0959-8049(16)33085.
    PubMed     Text format    


  58. SARTORE-BIANCHI A, Pietrantonio F, Amatu A, Milione M, et al
    Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Eur J Cancer. 2017;71:43-50.
    PubMed     Text format     Abstract available


  59. 'T LAM-BOER J, van der Stok EP, Huiskens J, Verhoeven RH, et al
    Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands.
    Eur J Cancer. 2017;71:109-116.
    PubMed     Text format     Abstract available


  60. CHAN AK, Siriwardena AK
    Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer.
    Eur J Cancer. 2017;71:51-52.
    PubMed     Text format    


    December 2016
  61. CREMOLINI C, Casagrande M, Loupakis F, Aprile G, et al
    Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Eur J Cancer. 2016 Dec 13. pii: S0959-8049(16)32534.
    PubMed     Text format     Abstract available


    November 2016
  62. HOLCH JW, Ricard I, Stintzing S, Modest DP, et al
    The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Eur J Cancer. 2016;70:87-98.
    PubMed     Text format     Abstract available


  63. DUCREUX M, Pignon JP
    Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?
    Eur J Cancer. 2016;69:178-179.
    PubMed     Text format    


  64. APARICIO T, Gargot D, Teillet L, Maillard E, et al
    Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Eur J Cancer. 2016 Nov 5. pii: S0959-8049(16)32475.
    PubMed     Text format     Abstract available


  65. ROTTENBERG Y, Ratzon NZ, Cohen M, Hubert A, et al
    Unemployment risk at 2 and 4 years following colorectal cancer diagnosis: a population based study.
    Eur J Cancer. 2016;69:70-76.
    PubMed     Text format     Abstract available


  66. GOEY KK, 't Lam-Boer J, de Wilt JH, Punt CJ, et al
    Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
    Eur J Cancer. 2016;69:166-177.
    PubMed     Text format     Abstract available


    October 2016
  67. BOUCHAHDA M, Boige V, Smith D, Karaboue A, et al
    Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Eur J Cancer. 2016;68:163-172.
    PubMed     Text format     Abstract available


  68. PRICE T, Kim TW, Li J, Cascinu S, et al
    Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Eur J Cancer. 2016;68:51-59.
    PubMed     Text format     Abstract available


  69. ZHAO Y, Fan D, Ru B, Cheng KW, et al
    6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Eur J Cancer. 2016;68:38-50.
    PubMed     Text format     Abstract available


    September 2016
  70. HEINEMANN V, Rivera F, O'Neil BH, Stintzing S, et al
    A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2016;67:11-20.
    PubMed     Text format     Abstract available


    August 2016
  71. MOL L, Ottevanger PB, Koopman M, Punt CJ, et al
    The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
    Eur J Cancer. 2016;66:138-143.
    PubMed     Text format     Abstract available


    July 2016
  72. CABALLERO-BANOS M, Benitez-Ribas D, Tabera J, Varea S, et al
    Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
    Eur J Cancer. 2016;64:167-174.
    PubMed     Text format     Abstract available


    June 2016
  73. BREUGOM AJ, Bastiaannet E, Boelens PG, Iversen LH, et al
    Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.
    Eur J Cancer. 2016;63:110-117.
    PubMed     Text format     Abstract available


    May 2016
  74. BANDO H, Doi T, Muro K, Yasui H, et al
    A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Eur J Cancer. 2016;62:46-53.
    PubMed     Text format     Abstract available


  75. LOGANADANE G, Servagi-Vernat S, Schernberg A, Schlienger M, et al
    Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series.
    Eur J Cancer. 2016;58:83-9.
    PubMed     Text format     Abstract available


    March 2016
  76. MCLACHLAN SA, Fisher RJ, Zalcberg J, Solomon M, et al
    The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).
    Eur J Cancer. 2016;55:15-26.
    PubMed     Text format     Abstract available


  77. HAAGENSEN EJ, Thomas HD, Mudd C, Tsonou E, et al
    Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Eur J Cancer. 2016;56:69-76.
    PubMed     Text format     Abstract available


    January 2016
  78. HELDER-WOOLDERINK JM, Blok EA, Vasen HF, Hollema H, et al
    Ovarian cancer in Lynch syndrome; a systematic review.
    Eur J Cancer. 2016;55:65-73.
    PubMed     Text format     Abstract available


  79. FORMICA V, Formica D, Formica G
    The 'death pace' in the CO.17 trial.
    Eur J Cancer. 2016;53:1-4.
    PubMed     Text format     Abstract available


  80. CASHIN PH, Mahteme H, Spang N, Syk I, et al
    Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    Eur J Cancer. 2016;53:155-62.
    PubMed     Text format     Abstract available


  81. NOREN A, Eriksson HG, Olsson LI
    Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study.
    Eur J Cancer. 2016;53:105-14.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: